Multiple agents and combination therapies available to patients with advanced colorectal cancer have significantly improved survival and provided an opportunity for individualization of care, allowing clinicians and patients to prioritize risks and benefits of comparable regimens.
S Yousuf Zafar, Jennifer E Marcello, Jane L Wheeler, Krista L Rowe, Michael A Morse, James E Herndon, and Amy P Abernethy.
Cancer Center Biostatistics; Division of Medical Oncology, Department of Medicine; and Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC.
J Oncol Pract. 2009 Sep 1;5(5):228-33.
AbstractMultiple agents and combination therapies available to patients with advanced colorectal cancer have significantly improved survival and provided an opportunity for individualization of care, allowing clinicians and patients to prioritize risks and benefits of comparable regimens.